Vasan Eye Care

Sector: Pharma & Healthcare (Eye Care Hospital Chain)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

Vasan Eye Care operates in the pharma & healthcare segment of the Indian market, with a presence noted in the eye care hospital chain category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where Vasan Eye Care is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in eye care hospital chain includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

Dec 2025 – Mar 2026

Vasan Eye Care continues to expand its reach under the ASG Eye Hospitals umbrella. ASG Eye Hospitals recently unveiled Vision 2030, a major expansion initiative backed by a Rs 2,000 crore investment commitment to scale operations to 600–700 centres nationwide [2,4]. In support of this growth, Vasan Eye Care and ASG Eye Hospitals entered into a pan-India partnership with Star Health Insurance to offer cashless eye care services, enhancing accessibility for insured patients [1]. The brand also commemorated a milestone, with its Marathahalli branch marking 14 years of advanced ophthalmic care [7], while a new advanced facility was launched in Shimoga on Independence Day 2025 [6].

The current phase of expansion builds on ASG Eye Hospitals' acquisition of Vasan Eye Care in early 2023, following prior regulatory and enforcement developments involving the original promoter [8,9,10]. On the clinical front, industry reports note improving early diagnosis of eye cancer in Hyderabad, though delays in detection remain a concern for the broader ophthalmology sector [5]. Vasan Eye Care has also engaged in road safety awareness activities, reflecting community-oriented outreach alongside its commercial growth agenda [3].

Sources (10)

1. Vasan Eye Care & ASG Eye Hospitals Partner with Star Health Insurance for Pan-India Cashless Eye Care - This Week India · This Week India · Tue, 02 Dec 2025
2. ASG Eye Hospital Unveils Vision 2030 With Rs 2,000 Cr Expansion Plan - BW Healthcare World · BW Healthcare World · Fri, 05 Dec 2025
3. Vasan Eye Care Drives Road Safety Awareness at Marathahalli - City Today News · City Today News · Sat, 24 Jan 2026
4. ASG Eye Hospital to invest ₹2,000 crore, scale to 600-700 centres - Business Standard · Business Standard · Thu, 04 Dec 2025
5. Early diagnosis of eye cancer improves in Hyderabad, yet delays remain a concern - The Times of India · The Times of India · Mon, 30 Mar 2026
6. “Sharper Vision for a Stronger Nation: Vasan Eye Care Shimoga Unveils Advanced Facility on 79th Independence Day” - City Today News · City Today News · Fri, 15 Aug 2025
7. Vasan Eye Care, Marathahalli, Celebrates 14 Years of Excellence in Advanced Ophthalmic Care - This Week India · This Week India · Mon, 10 Nov 2025
8. ASG Eye Hospitals takes operation control of Vasan Eye Care - The Economic Times · The Economic Times · Sat, 04 Mar 2023
9. ASG Eye Hospitals acquires TN-based Vasan Eye Care - The New Indian Express · The New Indian Express · Sun, 05 Mar 2023
10. Vasan eye care promoter death: ED says case to continue - The Indian Express · The Indian Express · Wed, 18 Nov 2020

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Vasan Eye Care occupies a position in the eye care hospital chain category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on eye care hospital chain benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the eye care hospital chain value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

Vasan Eye Care is a participant in the Indian eye care hospital chain category, which forms part of the broader Pharma & Healthcare space. The Indian eye care hospital chain market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Vasan Eye Care specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Vasan Eye Care mirrors the broader eye care hospital chain category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Vasan Eye Care as a peer benchmark within the eye care hospital chain category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Vasan Eye Care, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Vasan?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (eye care hospital chain) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Vasan and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Vasan Eye Care in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.